Camrelizumab Biosimilar - Research Grade

In stock
Only %1 left
SKU
ICH5003
Add to Compare
$300.00
Add to Wish List

Camrelizumab Biosimilar - Research Grade

Product Benefits:

ichorbio's Camrelizumab Biosimilar - Research Grade is manufactured in a cGMP compliant facility. Click here to view ichorbio's complete list of anti-PD-1 antibodies and biosimilars.

Size:

ichorbio's Camrelizumab biosimilar is available in the following sizes: 1mg, 5mg, 10mg, 20mg, 50mg, 100mg ichorbio regularly manufactures bulk multi-gram amounts of our Camrelizumab biosimilar - please contact us for pricing.

Target:

PD-1

Isotype:

IgG4 kappa

Other Names:

Programmed cell death protein 1, Pdcd1, CD279

Host:

CHO cells

Species Reactivity:

Human

Specificity:

Detects human PD-1.

Purification Method:

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background:

Camrelizumab biosimilar is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It is an IgG4 kappa immunoglobulin with an approximate molecular weight of 149 kDa.

Concentration:

1.0 - 5.0 mg/ml

Formulation:

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity:

>95% by SDS-PAGE and HPLC

Endotoxin:

≤ 0.75 EU/mg as determined by the LAL method

Storage:

Camrelizumab Biosimilar - Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Applications:

Functional Assays

Application Notes:

Each investigator should determine their own optimal working dilution for specific applications.

Isotype Control:

Bulk Human IgG4 Isotype Control (IB4) [ICH2257]

Use: ichorbio's Camrelizumab biosimilar is for research use only (RUO).
More Information
Concentration 13.17mg/ml
isotype IgG4 kappa
Host CHO cells
Write Your Own Review
You're reviewing:Camrelizumab Biosimilar - Research Grade
Your Rating
Back to Top